Prescription Opioid Addiction Treatment Study (POATS)
Public ClinicalTrials.gov record NCT00316277. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether treatment outcome for subjects dependent on prescription opioid analgesics can be improved by adding individual drug counseling to the prescription of buprenorphine/naloxone with standard medical management. This will be examined during: a) an initial four-week treatment with taper; b) a 12-week stabilization treatment for those who do not respond successfully to the initial treatment; and c) a long-term follow-up assessment at 1.5 years, 2.5 years, and 3.5 years after treatment.
Study identification
- NCT ID
- NCT00316277
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 653 participants
Conditions and interventions
Interventions
- Standard Medical Management (SMM) of Prescription Opiate Abuse Behavioral
- Enhanced Medical Management (EMM) of Prescription Opiate Abuse Behavioral
Behavioral
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Jun 30, 2009
- Completion
- Dec 31, 2012
- Last update posted
- Feb 5, 2013
2006 – 2013
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Integrated Substance Abuse Programs | Los Angeles | California | 90025 | — |
| San Francisco General Hospital | San Francisco | California | 94110 | — |
| East Indiana Treatment Center | Lawrenceburg | Indiana | 47025 | — |
| McLean Hospital, Alcohol and Drug Abuse Treatment Program | Belmont | Massachusetts | 02478 | — |
| North Shore - Long Island Jewish Health Systems | Glen Oaks | New York | 11004 | — |
| Bellevue Hospital Center | New York | New York | 10016 | — |
| St. Luke's Roosevelt Hospital Center | New York | New York | 10019 | — |
| ADAPT, Inc. | Roseburg | Oregon | 97470 | — |
| Behavioral Health Services of Pickens County | Pickens | South Carolina | 29671 | — |
| Homeward Bound, Inc. | Dallas | Texas | 75208 | — |
| Providence Behavioral Health Service | Everett | Washington | 98206 | — |
| Chestnut Ridge Hospital | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00316277, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2013 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00316277 live on ClinicalTrials.gov.